|
NSTC Subcommittee on Biological Sciences
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP
|
Advises and assists the Committee on Science and the National Science and Technology Council (NSTC) on Federal policies, procedures and plans in the biological sciences; also explore ways in which the Federal government can increase the overall effectiveness and productivity of its investment in biological sciences research, especially regarding issues that cut across agency boundaries.
|
|
NSTC Subcommittee on Biological Sciences -Interagency Synthetic Biology Working Group (BSSC-SBWG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
OD/OSP, NIBIB
|
Provides coordination and strategic planning to help ensure responsible innovation and significant advances in research in synthetic biology.
|
|
Nutrition Research Coordinating Committee (NRCC)
|
Committee, Work group, Advisory group, or Task Force
|
ACL, AHRQ, ASPE, CDC, FDA, HRSA, OASH
|
OD/DPCPSI/ONR
|
The Nutrition Research Coordinating Committee (NRCC) was established by the National Institutes of Health (NIH) Office of the Director in 1975 to improve communication and research coordination of nutrition activities within the NIH and across the federal government. Today it provides an open forum for members to discuss current and future nutrition research challenges and opportunities. The NRCC has broad representation from the NIH institutes and centers. In addition, liaisons from other federal offices and agencies also participate. The NRCC meets monthly, alternating between intra-NIH and interagency meetings. NRCC membership is open to any federal staff member interested in carrying out any trans-NIH or trans-agency nutrition research efforts.
|
|
Obesity Prevention and Control: Combined School-Based Interventions to Increase Healthier Food and Beverage Consumption and Physical Activity
|
Meeting/ Workshop
|
CDC
|
NHLBI
|
Ongoing participation on monthly calls by the Community Guide Coordinating Team.
|
|
Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD)
|
Research Initiative
|
CDC
|
NIAID
|
This is a study of the safety, adherence, and efficacy of a fixed-dose combination of drug tenofovir/lamivudine/dolutegravir (TLD) among HIV patients, including those co-infected with tuberculosis, receiving care at PEPFAR (President’s Emergency Plan for AIDS Relief) funded sites in resource limited countries.
|
|
Occupational Exposure Assessment of Emerging Per- and Polyfluoroalkyl Substances (PFAS)
|
Research Initiative
|
CDC
|
NIEHS
|
The primary objectives of this study are to identify PFAS compounds currently in use in commerce or industry and the companies, industries, and worker populations who are manufacturing, processing, or using PFAS products and to conduct targeted occupational exposure assessments in high- and moderate-PFAS volume industries. Based on the results of the exposure assessment, secondary objectives of this study are to assess health effects associated with PFAS exposure. To meet the objectives of this study, we propose four specific aims.
|
|
Office for Human Research Protections/Office of Extramural Research Training Initiative
|
Meeting/ Workshop
|
OS
|
OD/OER
|
The National Institutes of Health (NIH) collaborated with the OER"s Division of Human Subjects Research to provide comprehensive human subjects protection training at the fall NIH Virtual Meeting for the extramural community.
|
|
Office of AIDS Research Advisory Council (OARAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
OD/DPCPSI/OAR, OD, NIAID, OD/DPCPSI
|
The Office of AIDS Research Advisory Council (OARAC) provides advice to the Office of AIDS Research (OAR) Director on the planning, coordination, and evaluation of research and other HIV/AIDS activities conducted or supported by the National Institutes of Health (NIH). The OARAC advises the Secretary of Health and Human Services, the Assistant Secretary for Health, the Director of NIH, and the Director of OAR on HIV/AIDS research programs and the development and annual review of the comprehensive NIH Strategic Plan for HIV and HIV-Related Research.
|
|
Office of Justice Programs/HHS Medicolegal Death Investigation Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID, CC, NICHD
|
Identify short and long term goals to develop and implement programmatic activities that support the Medicolegal Death Investigation system.
|
|
Office of Science and Technology Mo99 Stakeholders Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA, OSG
|
NIBIB, NCI
|
The purpose of this working group is to coordinate the efforts of multiple stakeholders (Department of State, Department of Energy, Department of Homeland Security, Department of Health and Human Services, private sector) to establish a stable, long-term domestic supply of Mo99 (molybdenum-99) for medical purposes. Such a supply needs to be consistent with current international goals (to which the US is an active participant) of reduction in the use of high-enriched uranium in all reactors, including Mo99 production facilities, as well as full cost recovery solutions. The National Institutes of Health (NIH) staff attend stakeholders workshops, the last was held in the Spring of 2018. A symposium was scheduled in 2020 but was postponed due to COVID-19.
|